Greenwich LifeSciences Expands Clinical Trial Reach to Belgium
Greenwich LifeSciences, Inc. (NASDAQ: GLSI), a clinical-stage biopharmaceutical company, is taking significant strides in its mission to combat breast cancer. The company is expanding its pivotal Phase III clinical trial, FLAMINGO-01, to include Belgium. This trial investigates GLSI-100, an innovative immunotherapy aimed at preventing recurrences of breast cancer. The expansion marks a crucial step in increasing access to experimental treatments for patients across Europe.
Approval for Clinical Trial Expansion
The recent approval from European regulators allows Greenwich LifeSciences to initiate its clinical trial in Belgium, adding to its already established presence in countries like Spain, France, Germany, Italy, Poland, Romania, Ireland, and Portugal, along with sites in the United States.
Impact of Breast Cancer in Belgium
In Belgium, breast cancer remains the most frequently diagnosed cancer among women. Recent statistics indicate that over 11,000 new cases were reported in a year, accounting for approximately a third of all female cancer diagnoses. Disturbingly, breast cancer also tops the list as the leading cause of cancer-related deaths among women, highlighting the urgent need for effective treatment options.
Collaboration with Leading Medical Experts
To effectively implement the FLAMINGO-01 clinical trial in Belgium, Greenwich LifeSciences is collaborating with Dr. Patrick Neven, a prominent figure in gynecological oncology and the national principal investigator for the study. Dr. Neven brings a wealth of expertise, having published extensively in the field and actively participating in various scientific organizations.
Significance of the Collaboration
This partnership with Dr. Neven ensures that the clinical trial is conducted at the highest standard, utilizing his extensive experience in breast cancer research and treatment. The company’s CEO, Snehal Patel, expressed gratitude towards the steering committee for facilitating this collaboration and underscored the importance of conducting start-up activities in Leuven, a strategic location for accessibility across Belgium.
About the FLAMINGO-01 Trial
FLAMINGO-01 is a Phase III clinical trial designated to evaluate GLSI-100's safety and efficacy. This immunotherapy is specifically designed for HER2-positive breast cancer patients who have undergone previous treatment yet still face a risk of recurrence. The trial will encompass up to 150 sites globally, with plans to recruit approximately 500 patients for a double-blind study comparing GLSI-100 with a placebo.
Trial Design and Objectives
The groundwork laid in this trial aims to demonstrate meaningful advancements in invasive breast cancer-free survival outcomes. By employing a robust statistical methodology, researchers will monitor critical events that indicate the therapy's effectiveness. The interim analysis will provide insights as participant data accumulates, allowing timely evaluations of the treatment's success.
Understanding Breast Cancer and HER2 Positivity
At the heart of the research is the HER2 protein, a significant marker in various cancers, including nearly 75% of breast cancer cases. Targeting HER2 is essential, as it plays a crucial role in promoting cell growth and proliferation. Effective immunotherapies like GLSI-100 aim to harness the body’s immune system to combat tumors that exhibit this protein.
Greenwich LifeSciences and Their Commitment
Greenwich LifeSciences remains dedicated to advancing innovative treatments that focus on improving the lives of patients and their families affected by breast cancer. Their recent initiative to expand the FLAMINGO-01 trial exemplifies their commitment to research and development in the biopharmaceutical landscape.
Company Profile and Future Goals
The company not only focuses on developing GP2 as a promising immunotherapy candidate but also seeks to refine approaches to treatment based on patient feedback and clinical outcomes. By nurturing relationships with clinical researchers worldwide and emphasizing patient engagement, Greenwich LifeSciences aims to lead in breast cancer innovation.
Frequently Asked Questions
What is the FLAMINGO-01 clinical trial?
FLAMINGO-01 is a Phase III trial that evaluates the efficacy and safety of GLSI-100 for patients with HER2-positive breast cancer.
Who is Dr. Patrick Neven?
Dr. Patrick Neven is a leading expert in gynecological oncology and will serve as the national principal investigator for the trial in Belgium.
Why is the trial expanding to Belgium?
The expansion aims to provide more patients access to innovative treatment options and contribute to the understanding of breast cancer therapies in a European context.
What is GLSI-100?
GLSI-100 is an immunotherapy designed to trigger the immune response in HER2-positive breast cancer patients to prevent recurrence after surgery.
How can patients participate in the trial?
Potential participants can find more information on the trial and how to get involved through the company’s website or by contacting their team directly.
